Locally advanced colorectal cancer
Conditions
Interventions
camrelizumab groups:None
Chemotherapy Group:None
Oxaliplatin: 85 mg/m2, intravenous infusion over 2 hours, day 1.
Calcium folinate (Leucovorin): 400 mg/m2, intravenous infusion over 2 hours, day 1.
5-Fluorouracil: 2600–280
Sponsors
Harbin medical university cancer hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 75 years; 2.Clinically diagnosed rectal adenocarcinoma; 3.MRI-assessed stage II (T3-4N0M0) or stage III (T1-4N1-2M0) rectal cancer patients, with the distal margin located <12 cm from the anal verge, and without peritoneal metastasis or other distant metastases; 4.ECOG PS 0-1; 5.Treatment-naïve patients who have not previously received systemic chemotherapy, radiotherapy, local resection, or immune checkpoint inhibitor therapy for colorectal cancer, and have subsequently undergone at least 3 cycles of neoadjuvant therapy with either the FOLFOXIRI chemotherapy regimen or the FOLFOXIRI chemotherapy regimen combined with camrelizumab; 6.Good treatment compliance and no severe diseases in other vital organs; 7.Complete clinical data and follow-up information, with regular clinical follow-up examinations.
Exclusion criteria
Exclusion criteria: 1.Patients with active, suspected, or known autoimmune diseases were excluded; 2.Patients with a history of or concurrent other malignancies (excluding appropriately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma) were excluded; 3.Patients with incomplete treatment records or follow-up data were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Complete Response ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neoadjuvant Rectal Cancer Score;Objective Response Rate (ORR);Clinical Complete Response;Consolidated Tumor Complete Response;R0 Resection Rate;Percentage of Tumor Regression;Tumor Regression Grade;Event-Free Survival;Overall Survival;Sphincter Preservation Rate;safety; | — |
Countries
China
Contacts
Public ContactCuibinbin
Harbin medical university cancer hospital
Outcome results
None listed